Yu, Elmer <br/><br/>
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.  [electronic resource] 

 -  Drug and alcohol dependence  Sep 2008 
 - 158-68 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0376-8716 
<br/><br/><label>Standard No.: </label>10.1016/j.drugalcdep.2008.04.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic alpha-Agonists--adverse effects<br/>Adult<br/>Analgesics, Opioid<br/>Clonidine--adverse effects<br/>Data Collection<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Psychiatric Status Rating Scales<br/>Substance Abuse Detection<br/>Substance Withdrawal Syndrome--drug therapy<br/>Survival Analysis<br/>Treatment Outcome